Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Int J Cardiol ; 47(1): 5-11, 1994 Nov.
Article in English | MEDLINE | ID: mdl-7868285

ABSTRACT

Chagasic patients with advanced heart disease have fluid retention-dependent symptoms. Since fluid retention is mostly dependent on the renin-angiotensin-aldosterone system, chagasic patients with congestion related symptoms should have activation of the renin-angiotensin-aldosterone system. The purpose of this investigation was to determine the plasma renin activity baseline values of chagasic patients with and without congestive heart failure. Twenty-eight patients with positive serology for Chagas' disease were studied. Nineteen patients were asymptomatic (functional class I New York Heart Association) and nine were symptomatic (functional classes II-IV). Cardiac catheterization and ventricular cineangiography were performed on 20 patients. The symptomatic patients had significantly higher plasma renin activity levels (4.11 +/- 1.03 ng/ml/h) than the asymptomatic patients (1.08 +/- 0.11 ng/ml/h, P < 0.001) and the normal sedentary controls (1.65 +/- 0.22 ng/ml/h, P < 0.05, mean +/- S.E.). The plasma renin activity baseline values of the asymptomatic and symptomatic patients correlated directly with the baseline heart rate (r = 0.77, P < 0.0001). The symptomatic patients had larger ventricular volumes, moderately depressed ejection fractions and increased left ventricular end-diastolic pressures. The plasma renin activity baseline values also correlated directly with the left ventricular diastolic pressures (r = 0.70, P < 0.0006) and with the left ventricular diastolic (r = 0.66, P < 0.001) and systolic volumes (r = 0.67, P < 0.001). These results indicate that chagasic patients with fluid retention-dependent symptoms and hemodynamic evidence of left ventricular systolic dysfunction have activation of the renin-angiotensin-aldosterone system.


Subject(s)
Chagas Disease/blood , Heart Failure/etiology , Renin/blood , Adult , Analysis of Variance , Cardiac Catheterization , Chagas Cardiomyopathy/blood , Chagas Cardiomyopathy/physiopathology , Chagas Disease/physiopathology , Cineangiography , Electrocardiography , Female , Heart Failure/blood , Hemodynamics/physiology , Humans , Male , Middle Aged , Renin/biosynthesis , Ventricular Dysfunction, Left/blood , Ventricular Dysfunction, Left/etiology
2.
Int J Cardiol ; 41(2): 141-5, 1993 Sep.
Article in English | MEDLINE | ID: mdl-8282437

ABSTRACT

We studied eight patients to determine whether changes occur in the QRS amplitude when these patients are submitted to hemodialysis. The following variables were assessed before and after each (N = 28) hemodialysis session: (1) plasma sodium and potassium concentrations, (2) QRS amplitude, (3) the heart rate and its variability, (4) ventricular volumes, ventricular mass, ejection fraction and circumferential fiber shortening, (5) arterial pressure and end systolic stress, and (6) body weight. QRS amplitude was computed as the algebraic sum of the positive and negative waves of each QRS complex of the electrocardiogram. QRS amplitude changes were compared to body weight, ventricular volumes, ventricular mass, ejection fraction, circumferential fiber shortening, plasma potassium and sodium concentrations, arterial pressure, end systolic stress, heart rate, and R-R variability. After the hemodialysis sessions we found a significant increase (P = 0.0006) in QRS amplitude and a significant decrease in body weight (P = 0.0001), end diastolic volume (P = 0.043), plasma potassium concentration (P = 0.000001), end systolic stress (P = 0.025) and systolic arterial pressure (P = 0.023). Hemodialysis did not produce significant changes in the other variables. The statistical analyses performed did not show any significant influence of any of the measured variables on the QRS amplitude change. The QRS amplitude increases after hemodialysis but the cause of this increase is still unclear.


Subject(s)
Electrocardiography , Kidney Failure, Chronic/physiopathology , Renal Dialysis , Arrhythmias, Cardiac/diagnostic imaging , Arrhythmias, Cardiac/physiopathology , Arrhythmias, Cardiac/therapy , Blood Pressure/physiology , Body Weight/physiology , Cardiac Volume/physiology , Echocardiography , Heart Conduction System/physiopathology , Heart Rate/physiology , Humans , Kidney Failure, Chronic/diagnostic imaging , Kidney Failure, Chronic/therapy , Pericardial Effusion/diagnostic imaging , Pericardial Effusion/physiopathology , Pericardial Effusion/therapy , Potassium/blood , Sodium/blood , Stroke Volume/physiology , Systole/physiology
3.
Med Hypotheses ; 40(1): 33-7, 1993 Jan.
Article in English | MEDLINE | ID: mdl-8455464

ABSTRACT

According to the neurogenic theory of Chagas' heart disease, the cardiac parasympathetic abnormalities of chagasic cardiac patients are due to a selective destruction of the cardiac parasympathetic neurons. Trypanosoma cruzi would selectively destroy the cardiac vagal neurons, during the acute stage of the disease. However, these cardiac parasympathetic abnormalities are found mainly in chagasic patients who are in very advanced stages of the disease. Furthermore, the extent of cardiac parasympathetic involvement correlates with the degree of left ventricular dilation. Cardiac parasympathetic abnormalities, and a reciprocal sympathetic hyperactivity are also present in non-chagasic cardiac patients. Modern medical treatment, with sympatholytic drugs, prevents ventricular dilatation and prolongs life in these non-chagasic cardiac patients. Consequently, if chagasic cardiac patients have ventricular dilatation-related parasympathetic abnormalities; it is of the utmost importance to ask: first, do they also have a progressive activation of their neurohumoral systems?; and second, would they benefit from sympatholytic drugs?.


Subject(s)
Autonomic Nervous System/physiopathology , Chagas Cardiomyopathy/physiopathology , Chagas Cardiomyopathy/drug therapy , Chagas Cardiomyopathy/etiology , Heart Diseases/physiopathology , Humans , Models, Biological , Parasympathetic Nervous System/physiopathology , Sympatholytics/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...